ADMA SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations

Core Viewpoint - The law firm Kirby McInerney LLP is investigating ADMA Biologics, Inc. for potential violations of federal securities laws or other unlawful business practices, following allegations of improper revenue reporting practices [1][3]. Group 1: Allegations and Impact - On March 24, 2026, Culper Research published a report alleging that ADMA engaged in "Channel Stuffing" and reported misleading growth figures, indicating a real growth of -3% in 2025 compared to a reported growth of +20% [3]. - The report claims that ADMA incentivized a distributor to stock excess ASCENIV by offering rebates and extended payment terms, allowing the company to book revenues that did not reflect actual sales [3]. - Following the publication of the report, ADMA's share price fell by $2.26, or approximately 17%, from $13.59 on March 23, 2026, to $11.33 on March 24, 2026 [3]. Group 2: Ongoing Investigation - Currently, no lawsuit has been filed against ADMA, but the investigation by Kirby McInerney LLP is ongoing to determine if claims can be brought under federal securities laws [4]. - Investors who purchased ADMA securities or have relevant information are encouraged to contact the law firm for further discussion regarding their rights [4]. Group 3: Law Firm Background - Kirby McInerney LLP is a New York-based law firm specializing in securities, antitrust, whistleblower, and consumer litigation, with a history of recovering billions of dollars for shareholders in securities litigation [6].